Distinct lung cell signatures define the temporal evolution of diffuse alveolar damage in fatal COVID-19.

Saved in:
Bibliographic Details
Title: Distinct lung cell signatures define the temporal evolution of diffuse alveolar damage in fatal COVID-19.
Authors: Milross L; Newcastle University Translational and Clinical Research Institute, Newcastle upon Tyne, UK., Hunter B; Newcastle University Biosciences Institute, Newcastle upon Tyne, UK; Innovation Methodology and Application Research Theme, Biosciences Institute, Newcastle University, Newcastle upon Tyne, UK., McDonald D; Newcastle University Biosciences Institute, Newcastle upon Tyne, UK; Innovation Methodology and Application Research Theme, Biosciences Institute, Newcastle University, Newcastle upon Tyne, UK., Merces G; Newcastle University Biosciences Institute, Newcastle upon Tyne, UK; Innovation Methodology and Application Research Theme, Biosciences Institute, Newcastle University, Newcastle upon Tyne, UK., Thomson A; Newcastle University Translational and Clinical Research Institute, Newcastle upon Tyne, UK; Newcastle University Biosciences Institute, Newcastle upon Tyne, UK; Innovation Methodology and Application Research Theme, Biosciences Institute, Newcastle University, Newcastle upon Tyne, UK., Hilkens CMU; Newcastle University Translational and Clinical Research Institute, Newcastle upon Tyne, UK., Wills J; Department of Veterinary Medicine, University of Cambridge, Cambridge, UK., Rees P; Department of Biomedical Engineering, Swansea University, Wales, UK; Imaging Platform, Broad Institute of MIT and Harvard, 415 Main Street, Boston, Cambridge, MA, USA., Jiwa K; Department of Cellular Pathology, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK., Cooper N; Department of Cellular Pathology, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK., Majo J; Department of Cellular Pathology, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK., Ashwin H; York Biomedical Research Institute, Hull York Medical School, University of York, York, UK., Duncan CJA; Newcastle University Translational and Clinical Research Institute, Newcastle upon Tyne, UK; Department of Infection and Tropical Medicine, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK., Kaye PM; York Biomedical Research Institute, Hull York Medical School, University of York, York, UK., Bayraktar OA; Wellcome Sanger Institute, Hinxton, Cambridge, UK., Filby A; Newcastle University Biosciences Institute, Newcastle upon Tyne, UK; Innovation Methodology and Application Research Theme, Biosciences Institute, Newcastle University, Newcastle upon Tyne, UK. Electronic address: andrew.filby@newcastle.ac.uk., Fisher AJ; Newcastle University Translational and Clinical Research Institute, Newcastle upon Tyne, UK; Institute of Transplantation, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK. Electronic address: a.j.fisher@newcastle.ac.uk.
Source: EBioMedicine [EBioMedicine] 2024 Jan; Vol. 99, pp. 104945. Date of Electronic Publication: 2023 Dec 23.
Publication Type: Journal Article
Journal Info: Publisher: Elsevier B.V Country of Publication: Netherlands NLM ID: 101647039 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2352-3964 (Electronic) Linking ISSN: 23523964 NLM ISO Abbreviation: EBioMedicine Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:2352-3964
DOI:10.1016/j.ebiom.2023.104945